Please login to the form below

Not currently logged in

Dr Engelbert Tjeenk Willink joins Allecra Therapeutics

The French pharma company has also appointed Dr Leon Hooftman

Dr Engelbert Allecra Therapeutics has appointed Dr Engelbert Tjeenk Willink as chairman of the board as the company enters its next phase of development.

Previously a member of the board of managing directors at Boehringer Ingelheim GmbH, Willink (pictured right) brings over 25 years experience within the pharmaceutical industry.

He said: “Allecra is a dynamic company with the potential to make a significant impact on the growing and widespread epidemic of drug-resistant bacterial infections.

“I am delighted to have the opportunity to contribute towards its success.”

Dr Leon HooftmanDr Leon Hooftman also joins Allecra as its new chief medical officer (CMO), bringing over 20 years of experience in biopharmaceutical drug development.

Most recently serving as CMO for Polyphor, Hooftman (pictured left) has held several senior positions for the likes of Celltech Group plc and Chroma Therapeutics.

He said: “Allecra is working directly on Gram-negative resistant infections in the hospital, an area of urgent unmet medical need recently highlighted by both the World Health Organization (WHO) and by the US Center for Disease Control (CDC).

"Allecra’s technology provides an important new treatment for hospital clinicians who are grappling with these types of infection.”

Hooftman’s new role will see him focus on combating multi drug-resistant Gram-negative bacterial infections.

Nicholas Benedict, CEO at Allecra, said: “The appointments of Bert and Leon mark a watershed in the development of Allecra.

“Regulatory authorities have recognised the potential that Allecra’s novel antibiotic may contribute towards solving the crisis of resistant bacterial infections, and out lead development programme has been significantly expedited.

“With these new appointments, Allecra is strengthening its expertise as the company advances its development activities for a potentially important new antibiotics treatment for patients.”

7th April 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...